Detecting cancer before it strikes again: pioneering Bone Marrow-on-Chip technology to predict tumor relapse and transform patient outcomes
OUR VISION
The vision of the EU-funded project BuonMarrow is to revolutionize cancer treatment by understanding and predicting cancer recurrence before it is visible through conventional methods. By developing a biological sensor for early detection of tumor relapse, our groundbreaking research aims to improve the survival rates of lung cancer patients.
MULTIDISCIPLINARY TEAM
BuonMarrow brings together a multidisciplinary Consortium with complementary backgrounds from the clinical, biological and engineering fields, merging them to achieve a radically new approach at the frontier between preclinical research and clinical diagnosis:
- Clinical oncology
- Stem cells biology
- Immunology
- Microtechnologies
- Optical sensors
PARTNERS
THE PROJECT IN NUMBERS
4
3
3
3
Partners
Countries
Millions
Years
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101130604. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.